Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

MorphoSys began as a research and development technology provider 30 years ago, which positioned us as a valuable partner to pharmaceutical manufacturers worldwide. This empowered our evolution into a fully integrated biopharmaceutical company, and our growth over the past 15 years can only be attributed to the dedicated and passionate people driving our mission forward: More life for people with cancer.
Explore our open positions and learn more about our core values, mission and work at www.morphosys.com.

When Sponsors need to know that their clinical trial is properly managed, the data is high quality, and their CRO is keeping them safe, they turn to Stiris’ depth of experience to manage their studies. Stiris Research is a full-service, Clinical Trial Management company specialized in conducting Phase I through IIIB trials for biotechnology and biopharmaceutical companies. We are the only CRO that was formed from listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs. Stiris was built by biotech, for biotech.